IO vs IV Vancomycin in Tourniquetless TKA

Description

Purpose of this study is to compare the efficacy of intravenous and intraosseous antibiotic administration techniques during tourniquetless total knee arthroplasty.

Conditions

Infection, Surgical Site

Talk to us

Study Overview

On this page

Study Details

Study overview

Purpose of this study is to compare the efficacy of intravenous and intraosseous antibiotic administration techniques during tourniquetless total knee arthroplasty.

Intraosseous Vancomycin vs Intravenous Vancomycin in Tourniquetless Primary Total Knee Arthroplasty

IO vs IV Vancomycin in Tourniquetless TKA

Condition
Infection, Surgical Site
Intervention / Treatment

-

Contacts and Locations

Houston

Houston Methodist Hospital Outpatient Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patient is undergoing a primary total knee arthroplasty.
  • * Patient is able to understand the study design and intervention and gives informed consent to participate in the study. No LAR consents will be utilized for this study.
  • * Age \>18 years.
  • * Total knee arthroplasty performed without the use of a tourniquet.
  • * Previous surgery on the knee (including arthroscopic knee surgery)
  • * BMI above 35
  • * Contraindication to receiving vancomycin, cefepime, ancef, or other standard of care pre-operative antibiotic (allergy, medical issue, etc).
  • * Inability to locate the tibial tubercle or administer the IO infusion
  • * Refusal to participate
  • * Uncontrolled Diabetes Mellitus type 1 or 2, defined as Hemoglobin A1C \>7.5.
  • * Immunocompromised or immunosuppressed patients (HIV, Hep C, End-Stage Renal Disease, dialysis, transplant, chemo/radiation treatment in last 6 months, and immunosuppresive medications)

Ages Eligible for Study

19 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

The Methodist Hospital Research Institute,

Study Record Dates

2024-01-25